About GRI Bio
GRI Bio is a publicly listed company based in San Diego (United States) founded in 2009. Small molecules targeting the regulation of Natural killer T cells to treat liver diseases. GRI Bio has raised $10.09 million across 2 funding rounds. The company has 4 employees. GRI Bio offers products and services including GRI-0621 and GRI-0803. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is GRI Bio, Inc. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
GRI Bio was founded in 2009 as a development-stage biotechnology company based in San Diego, United States. Small molecule therapeutics are developed by the firm to address liver diseases through regulation of Natural killer T cells. The lead candidate, GRI-0621, an oral inhibitor of type 1 NKT cells, is currently in Phase 2b clinical trials for non-alcoholic steatohepatitis and alcoholic liver disease.
- Headquarters San Diego, United States
- Employees 4
- Stage Public
- SectorsHealthcare
- Website gribio.com
- Social LinkedIn X
- Legal Name Gri Bio, Inc.
- Net Profit-$11.96 M (USD)-45.68as on Dec 31, 2025
- EBITDA-$11.97 M (USD)-45.46as on Dec 31, 2025
- Total Equity Funding$10.09M (USD)
in 2 rounds
- Latest Funding Round$5.71M (USD), Series A
Nov 2018
- Employee Count4
Products & Services of GRI Bio
GRI Bio offers a comprehensive portfolio of products and services, including GRI-0621 and GRI-0803.
NKT cell modulator targeting inflammatory diseases.
NKT cell modulator for fibrotic and autoimmune conditions.
Funding Insights of GRI Bio
GRI Bio has successfully raised a total of $10.09M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $5.71 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.09M
- Total Rounds 2
- Last Round Series A — $5.71M
- First Round $4.38M
(Apr 2015)
All 2 funding rounds of GRI Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $5.71M | Series A | – | – | – |
| Apr 2015 | $4.38M | Series A | – | – | – |
People of GRI Bio
1 people are tracked at GRI Bio (1 in leadership); the tracked headcount is 4.
| Name | Role | Group |
|---|---|---|
Marc Hertz | President & Chief Executive Officer | Leadership |
Complete people profiles for GRI Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GRI Bio
GRI Bio is a publicly listed company on the NASDAQ with ticker symbol GRI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Apr 2023
- Listed onNASDAQ: GRI
- Listed entityGRI Bio, Inc.
- Exchange sectorHealth technology
- ISINUS3622AW5029
- Share price$1.55 (-1.27% on the day) · 2026-10-13
- Market capitalisation$3.4M
- EPS (diluted, trailing year)$-43.74
- Volume (last session)35,262
Financials of GRI Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$12.0M | -$12.0M | |
| 2024 | -$8.2M | -$8.2M | |
| 2023 | -$13.0M | -$11.3M | |
| 2022 | -$3.2M | -$2.2M | |
| 2021 | -$9.3M | -$9.2M |
Detailed financial statements for GRI Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GRI Bio
4 dated milestones of GRI Bio across 14 years, from founding to its latest funding, stage changes and deals.
- Founded GRI Bio is founded.
- Funding First funding round of $4.4M.
- Funding Latest funding round, Series A, of $5.7M.
- IPO Lists on the stock exchange (IPO).
Competitors of GRI Bio
GRI Bio has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of GRI Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GRI Bio
The website of GRI Bio (gribio.com) receives about 3.1K visits a month.
- Monthly visits3.1K
▲ 74.7% vs previous month
Websites whose visitors overlap most with GRI Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| genelux.com | 100% | 3.1K | #5,486,231 | View details | |
| ventrixbio.com | 92% | 1.8K | #8,229,176 | View details | |
vastekgroup.com | vastekgroup.com | 92% | #4,627,539 | – | |
| abdesignlabs.com | 91% | 4.7K | #4,128,811 | View details | |
| nanome.ai | 91% | 3.9K | #4,650,815 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for GRI Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as GRI Bio (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gri Bio
Complete news archive for GRI Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GRI Bio
GRI Bio was founded in 2009 and raised its 1st funding round 6 years after it was founded.
GRI Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
GRI Bio is a funded company, having raised a total of $10.09M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.38M, raised on Apr 2015.
GRI Bio has 4 employees.
GRI Bio was founded in 2009 as a development-stage biotechnology company based in San Diego, United States. Small molecule therapeutics are developed by the firm to address liver diseases through regulation of Natural killer T cells. The lead candidate, GRI-0621, an oral inhibitor of type 1 NKT cells, is currently in Phase 2b clinical trials for non-alcoholic steatohepatitis and alcoholic liver disease.
GRI Bio's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.
GRI Bio offers GRI-0621 and GRI-0803.
Yes, GRI Bio is publicly traded on NASDAQ under the ticker symbol GRI.
GRI Bio operates through Gri Bio, Inc..